tetano
Editor, Senior Moderator
Respir Investig
. 2020 Sep 19;S2212-5345(20)30124-6.
doi: 10.1016/j.resinv.2020.08.006. Online ahead of print.
Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
J Guiot[SUP] 1 [/SUP], M Henket[SUP] 2 [/SUP], A N Frix[SUP] 2 [/SUP], M Delvaux[SUP] 2 [/SUP], A Denis[SUP] 2 [/SUP], L Giltay[SUP] 2 [/SUP], M Thys[SUP] 3 [/SUP], F Gester[SUP] 2 [/SUP], M Moutschen[SUP] 4 [/SUP], J L Corhay[SUP] 2 [/SUP], R Louis[SUP] 2 [/SUP], COVID-19 clinical investigators of the CHU de Li?ge
Collaborators, Affiliations
Abstract
Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
Results: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.
Keywords: COVID-19; Clinical epidemiology; Interstitial lung diseases; Lung fibrosis.
. 2020 Sep 19;S2212-5345(20)30124-6.
doi: 10.1016/j.resinv.2020.08.006. Online ahead of print.
Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
J Guiot[SUP] 1 [/SUP], M Henket[SUP] 2 [/SUP], A N Frix[SUP] 2 [/SUP], M Delvaux[SUP] 2 [/SUP], A Denis[SUP] 2 [/SUP], L Giltay[SUP] 2 [/SUP], M Thys[SUP] 3 [/SUP], F Gester[SUP] 2 [/SUP], M Moutschen[SUP] 4 [/SUP], J L Corhay[SUP] 2 [/SUP], R Louis[SUP] 2 [/SUP], COVID-19 clinical investigators of the CHU de Li?ge
Collaborators, Affiliations
- PMID: 32978099
- DOI: 10.1016/j.resinv.2020.08.006
Abstract
Introduction: Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
Methods: We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
Results: We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Conclusion: Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.
Keywords: COVID-19; Clinical epidemiology; Interstitial lung diseases; Lung fibrosis.